An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Evolus, Inc. (NASDAQ: EOLS) granted 28,328 restricted stock units (RSUs) to 7 non-executive employees under the 2023 Inducement Incentive Plan, with vesting over 4 years.
Positive
None.
Negative
None.
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in December of an aggregate of 28,328 restricted stock units (RSUs) of the company’s common stock to 7 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board of directors under the Evolus’ 2023 Inducement Incentive Plan, with a grant date and vesting commencement date of December 7, 2023, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest 25% on each annual anniversary of the vesting commencement date. The awards are subject to the terms and conditions of the 2023 Inducement Incentive Plan and the terms and conditions of the RSU agreement covering the grant, including requirements to remain continuously employed on each vesting date.
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), globally licensed under the brand name Nuceiva®. The product is manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, a line of five unique dermal fillers currently in late-stage development. Visit us at www.evolus.com, and follow us on LinkedIn, Twitter, Instagram or Facebook.
Jeuveau® and Nuceiva® are registered trademarks of Evolus, Inc.
Evolysse™ is a trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
How many restricted stock units (RSUs) did Evolus, Inc. (EOLS) grant to its employees?
Evolus, Inc. (EOLS) granted 28,328 restricted stock units (RSUs) to 7 newly hired non-executive employees.
Under which plan were the awards approved for the employees?
The awards were approved under Evolus' 2023 Inducement Incentive Plan.
What is the vesting schedule for the RSUs?
The RSUs vest 25% on each annual anniversary of the vesting commencement date.
What are the conditions for the RSU awards?
The awards are subject to the terms and conditions of the 2023 Inducement Incentive Plan and the RSU agreement, including requirements to remain continuously employed on each vesting date.
